European Biotech Acquisition Overview
Latest ROE for European Biotech Acquisition: 2.89% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow2.89%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
European Biotech Acquisition (EBAC) currently reports a ROE of 2.89%. That is below the sector sector average of 11.73%. Use the charts on this page to explore European Biotech Acquisition's ROE history and peer comparisons.
European Biotech Acquisition's ROE of 2.89% is lower than the its sector sector average of 11.73%. That is roughly 75.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but European Biotech Acquisition's current 2.89% should be judged against industry norms (sector average: 11.73%) and against EBAC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 2.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.73%. From there, open related valuation or income-statement pages for European Biotech Acquisition, and consider following EBAC for alerts when major investors trade the stock.
